Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05822245 · ClinicalTrials.gov registry record · Phase 1
A Study of PER-001 in Participants With Open-Angle Glaucoma
A Phase 1 study of Open Angle Glaucoma, sponsored by Perfuse Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05822245 is a Phase 1 study of Open Angle Glaucoma that is active but no longer recruiting, run by Perfuse Therapeutics. The registered enrollment target is 36 participants, below the 333-participant average among 28 other Open Angle Glaucoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05822245, a Phase 1 study of Open Angle Glaucoma, is active but no longer recruiting, sponsored by Perfuse Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical study has two phases: Phase 1 and Phase 2a. Phase 1 is an open-label, single ascending dose (SAD), while Phase 2a is a randomized, single-masked (participant) with a sham control.
Conditions Studied
Interventions
- DRUG PER-001 Intravitreal Implant - Low Dose
- DRUG PER-001 Intravitreal Implant - High Dose
- DRUG PER-001 Intravitreal Implant - Sham
Study Locations (1)
California
- Perfuse Therapeutics, Inc. - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-05-25 |
| Est. Completion | 2026-04-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05822245
The ClinicalTrials.gov registry entry for NCT05822245 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 333-participant average among 28 other Open Angle Glaucoma trials with a reported enrollment target (89% lower). The listed sponsor is Perfuse Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Open Angle Glaucoma appearing as the primary indexed condition, and to 3 interventions - of which PER-001 Intravitreal Implant - Low Dose is the first listed.
NCT05822245 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05822245 about?
NCT05822245 is a clinical study titled "A Study of PER-001 in Participants With Open-Angle Glaucoma". This clinical study has two phases: Phase 1 and Phase 2a. Phase 1 is an open-label, single ascending dose (SAD), while Phase 2a is a randomized, single-masked (participant) with a sham control.
What is the current status of trial NCT05822245?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2023-05-25. Estimated completion is 2026-04-04.
What conditions does trial NCT05822245 study?
This clinical trial studies the following conditions: Open Angle Glaucoma.
What interventions are being tested in trial NCT05822245?
The interventions under investigation include: PER-001 Intravitreal Implant - Low Dose (DRUG), PER-001 Intravitreal Implant - High Dose (DRUG), PER-001 Intravitreal Implant - Sham (DRUG).
Who is sponsoring clinical trial NCT05822245?
This trial is sponsored by Perfuse Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05822245 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Open Angle Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
RECRUITING · Phase 1
-
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 1
-
Study of ANX007 in Participants With Primary Open-angle Glaucoma
COMPLETED · Phase 1
-
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
RECRUITING · Phase 4
-
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
RECRUITING · NA
-
Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.